Today, through DBS Consulting, I support Pharma and Biotech companies as a senior advisor, consultant and interim executive.

A Career Across the Drug Development Lifecycle

I started my career with a degree in Chemistry and a PhD in Pharmaceutical Chemistry at the University of Münster (Germany), followed by a Lise-Meitner postdoctoral fellowship at the University of Vienna (Austria).

In 2002, I joined the Antibiotic Research Institute (ABRI) of Sandoz in Vienna, where I worked in analytical chemistry, bioanalysis and laboratory management.

In 2006, I joined Nabriva Therapeutics, where I spent more than 17 years in progressively senior scientific and management roles.

As Senior Director DMPK, I was responsible for bioanalytical activities and several areas of ADME/DMPK, including drug metabolism, drug transporters and plasma protein binding. I led an internal bioanalytical laboratory and managed external bioanalytical and ADME studies supporting both non-clinical and clinical development.

I was also a member of the non-clinical and clinical R&D teams and contributed to regulatory submissions for Xenleta® (lefamulin).

From 2015 onwards, I additionally held Managing Director under Austrian Trade Law, with responsibility for compliance, facility-related matters, health and safety and other operational aspects of the Vienna site.

From 2021 to 2023, I served as Managing Director of Nabriva Therapeutics GmbH, with corporate responsibility for the Austrian site.

---

Selected Track Record

Lefamulin / XENLETA^®

One of the highlights of my career has been the opportunity to contribute to the discovery and development of the novel antibiotic lefamulin from early discovery through preclinical and clinical development to regulatory approval.

I contributed to bioanalysis, ADME/DMPK and regulatory activities and was a co-author of regulatory submissions supporting the US, European and Canadian approvals of Xenleta®.

The FDA approved lefamulin (XENLETA^®) in August 2019, followed by approval in Europe and Canada in 2020.

This experience gave me first-hand insight into the complexity of moving a small-molecule drug candidate through the complete development lifecycle — from discovery to regulatory approval.

Building and Managing a Life Science Facility

Following the closure of Nabriva’s Austrian site in 2023, I joined InnoFly BioCenter (IBC) GmbH as Site Head and Managing Director under Austrian Trade Law.

I was responsible for establishing and managing IBC’s laboratory facility in Vienna, providing infrastructure for several biotechnology companies and start-ups.

My responsibilities covered not only laboratory infrastructure, but also operations, HSE, facility management, organizational processes and the coordination of multiple stakeholders.

From 2024 to the end of 2025, I additionally served as Managing Director of IBC.

Building R&D Capabilities in Biotech

In parallel, I joined Rockfish Bio AG in 2024 as Director DMPK/ADME.

There, I helped establish the company’s non-clinical ADME/DMPK program for novel small-molecule senolytics, covering areas such as plasma and organ PK, drug metabolism, drug transporters and plasma protein binding.

I was a member of the R&D team and additionally established the company’s HSE concept.

I left Rockfish Bio in December 2025 following the temporary cessation of its operations.

---

What I Bring

Scientific Depth

More than 25 years of experience across pharmaceutical chemistry, drug discovery, DMPK/ADME, bioanalysis and small-molecule drug development.

Leadership

More than 10 years of senior management and Managing Director experience in Pharma and Biotech.

Hands-on Execution

Experience building R&D functions, laboratories, operational infrastructure and external partnerships — and taking responsibility for implementation.

Strategic Perspective

The ability to connect scientific data and development strategy with organizational, operational and business considerations.

Resilience & Preparedness

Experience in HSE, operational risk management and Business Continuity Management (BCM), including preparedness for pandemic, blackout and other Black Swan events.

---

My Current Focus

Through DBS Consulting, I now support pharmaceutical and biotechnology companies that need experienced scientific, operational or executive support.

My focus includes:

• Executive and Interim Management
• R&D and Drug Development Advisory
• DMPK/ADME and Bioanalysis
• Scientific Due Diligence
• CRO and external partner management
• R&D and laboratory operations
• Business Continuity Management and organizational resilience

I am particularly interested in supporting organizations during critical development, growth, transition and transformation phases.

---

Based in Vienna. Working Internationally.

I am based in the Vienna area, Austria, and work with Pharma and Biotech organizations in Austria and internationally.

For more information about my services, please visit Services I Can Offer.

For a detailed overview of my professional experience, publications and qualifications, please see my CV (two-pager, detailed version) and List of Publications.

Let’s Talk

If you are facing a complex scientific, development, organizational or operational challenge and need experienced support, I would be pleased to discuss how I could contribute (Contact).